Connect your AI

MAZE MAZE Change in Other Liabilities

Change in Other Liabilities at other companies

Vertex PharmaceuticalsVRTX

$23.1M+5.0%

Septerna, Inc.SEPN

$100K—

Olema Pharmaceuticals, Inc.OLMA

$1.3M+112%

Zevra Therapeutics, Inc.ZVRA

$416K-25.7%

Relay Therapeutics, Inc.RLAY

$384K+225%

Cogent Biosciences, Inc.COGT

$29K+480%

Other financials

Income statement

Revenue$20.0M—

Operating income-$26.6M+25.0%

Net income-$24.2M+26.2%

EPS (diluted)-$0.45+60.9%

Balance sheet

Cash & equivalents$198.8M-32.5%

Total debt$61.2M+137%

Total equity$341.7M+17.0%

Total assets$419.7M+26.1%

Cash flow

Operating cash flow-$39.1M-32.5%

CapEx$93.0K-68.9%

Free cash flow-$39.2M-31.5%

Valuation

Market cap$1.48B+201%

Enterprise value$1.34B—

P/S7.9×—

Profitability

Operating margin-71.5%—

Net margin-65.4%—

FCF margin-65.1%—

Returns & leverage

Return on equity-38.7%—

Debt / equity0.2×+0.1×

Current ratio17.9×+1.8×

Where this comes from

Reported directly by MAZE in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities.

The official record: MAZE’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about MAZE's change in other liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is MAZE's change in other liabilities?: MAZE (MAZE) reported change in other liabilities of -$706K in Q1 2026.
How has MAZE's change in other liabilities changed year-over-year?: MAZE's change in other liabilities increased by 33.6% year-over-year, from -$1.06M to -$706K.
What does change in other liabilities mean?: Change in miscellaneous liabilities affecting operating cash flow.